A pair of developments spotlight both regulatory and manufacturing progress for genome engineering. First, Bioprocessing Summit speaker Kok-Seong Lim discussed how personalized CRISPR gene-editing therapies built using LNP-mRNA platforms may be standardized through locked lipid formulations and manufacturing process parameterization, even as patient-specific target genes change. Lim argued that standardizing key elements could improve scalability and reproducibility, and suggested that regulatory CMC datasets might be harmonized across patients by tailoring impurity profiling and stability studies to the shorter timeframe of individualized treatments. The talk also referenced ongoing collaborations connected to Baby KJ and clinical trials for subsequent patient cohorts. Second, these manufacturing and CMC discussions arrive alongside policy scrutiny on how regulatory guidance is interpreted by sponsors, highlighting the need to align evidence packages with FDA expectations as individualized gene-editing expands. Together, the focus on CMC standardization and regulatory framing reflects a shift from feasibility toward industrialization for personalized genome engineering.